Calcitriol

證據等級: L5

預測適應症: 7 個

Calcitriol: From Hypoparathyroidism and Renal Osteodystrophy to Hereditary Hypophosphatemic Rickets

One-Sentence Summary

Calcitriol (1,25-dihydroxyvitamin D3) is the biologically active form of vitamin D, globally recognized for treating calcium-phosphate metabolism disorders including hypoparathyroidism and renal osteodystrophy, though it currently holds no marketing authorization in the Netherlands. The TxGNN model identifies 7 predicted repurposing candidates across this evidence pack; among these, Hereditary Hypophosphatemic Rickets carries the strongest actionable evidence, supported by 7 clinical trials and 20 publications. This indication is graded at Evidence Level 2 with a Proceed with Guardrails recommendation.

Quick Overview

Item	Content
Original Indication	Not currently registered in the Netherlands; globally recognized for hypoparathyroidism, renal osteodystrophy, and vitamin D-dependent rickets
Predicted New Indication	Hereditary Hypophosphatemic Rickets
TxGNN Prediction Score	99.28%
Evidence Level	L2
NL Market Status	Not registered
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Calcitriol is 1,25-dihydroxyvitamin D3, the hormonally active end-metabolite of vitamin D produced in the proximal renal tubule by the enzyme CYP27B1 (1α-hydroxylase). It acts through the vitamin D receptor (VDR), a nuclear receptor widely expressed in the intestine, kidney, bone, and parathyroid glands. Core pharmacological effects include stimulation of intestinal calcium and phosphate absorption, suppression of parathyroid hormone (PTH) secretion, and direct promotion of bone mineralisation. Although formal DrugBank mechanism-of-action data was not available in this evidence pack, calcitriol’s pharmacology is extensively characterised in the scientific literature cited below.

In hereditary hypophosphatemic rickets — most commonly X-linked hypophosphatemia (XLH, caused by loss-of-function mutations in PHEX) — excess FGF23 production from bone simultaneously suppresses renal phosphate reabsorption and inhibits CYP27B1 activity. The result is a paradoxical state: hypophosphatemia combined with inappropriately low or normal calcitriol levels, despite the anticipated compensatory upregulation. This dual deficiency drives defective growth plate cartilage mineralisation and osteomalacia. Exogenous calcitriol supplementation directly bypasses FGF23-mediated 1α-hydroxylase suppression, restores intestinal phosphate and calcium uptake, reduces compensatory secondary hyperparathyroidism, and thereby improves skeletal mineralisation.

Calcitriol combined with neutral phosphate supplementation served as the standard of care for hereditary hypophosphatemic rickets for several decades, until the 2018 EMA approval of burosumab — an anti-FGF23 monoclonal antibody targeting the upstream pathophysiology. The TxGNN prediction at rank 7 is therefore mechanistically well-grounded and consistent with established clinical practice. Within the Dutch healthcare context, this represents a repositioning opportunity particularly for patients in whom burosumab is inaccessible, contraindicated, or for whom conventional therapy remains the preferred approach.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03748966	Early Phase 1	Active, Not Recruiting	20	Calcitriol monotherapy (without phosphate supplementation) in children and adults with XLH over 1 year with dose escalation; tests hypothesis that calcitriol alone improves serum phosphate levels and skeletal mineralisation without increasing nephrocalcinosis
NCT03820518	Phase 4	Unknown	100	Head-to-head comparison of high-dose vs. low-dose calcitriol combined with neutral phosphate in children with XLH; aims to establish evidence-based weight-adjusted dosing guidelines
NCT04846647	N/A (Observational)	Completed	260	Prospective observational study characterising FGF23 hypersecretion in 260 hypophosphatemia patients; provides mechanistic evidence that FGF23 inhibits calcitriol synthesis, directly supporting the rationale for calcitriol supplementation
NCT06046820	Phase 3	Active, Not Recruiting	27	Phase 3 RCT of INZ-701 (ENPP1 enzyme replacement therapy) in children with ENPP1 deficiency; provides treatment landscape context for FGF23-related phosphate disorders; calcitriol may function as an adjunct or comparator arm
NCT06921720	N/A	Not Yet Recruiting	65	Mechanistic study using ³¹P-MRS spectroscopy to measure ATP concentrations in phosphate diabetes (XLH); explores energy metabolism pathophysiology in hypophosphatemia relevant to calcitriol’s therapeutic target
NCT01526304	N/A (Observational)	Unknown	150	Cross-sectional study of FGF23, Klotho, and sclerostin in kidney stone formers; indirectly explores the phosphate–vitamin D regulatory axis central to calcitriol’s mechanism of action
NCT00844740	N/A	Withdrawn	0	Planned study of cinacalcet add-on to standard calcitriol + phosphate in familial hypophosphatemic rickets; withdrawn before enrollment — included for completeness; no evidential value

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40295317	2025	Clinical Guideline Review	Calcified Tissue International	Comprehensive XLH diagnosis and therapy review: FGF23 excess reduces calcitriol synthesis; calcitriol + phosphate remains standard care in many clinical settings; monitoring recommendations included
39181153	2024	Review	Lancet	Authoritative X-linked hypophosphataemia primer: PHEX mutation → FGF23 excess → decreased calcitriol synthesis → impaired intestinal phosphate absorption → defective bone mineralisation
36446330	2022	Review	Hormone Research in Paediatrics	Historical and mechanistic review of rickets and vitamin D therapy; places calcitriol in the treatment hierarchy for hereditary hypophosphatemic rickets subtypes and outlines metabolic management
38988138	2024	Cohort/Review	J Bone and Mineral Research	Clinical case series with narrative review of hypophosphatemic rickets and short stature; illustrates the biochemical profile (low phosphorus, elevated ALP, low/normal calcitriol) typical of XLH requiring active vitamin D intervention
17117305	2006	Review	Arq Bras Endocrinol Metab	Pathophysiology review of hereditary hypophosphatemic conditions including XLH, ADHR, and ARHR; confirms inappropriately normal or low calcitriol as a shared feature across subtypes, requiring supplementation
6252463	1980	Clinical Trial	New England Journal of Medicine	Landmark comparative trial in 11 children: phosphate alone vs. phosphate + ergocalciferol vs. phosphate + calcitriol; calcitriol combination was superior in enhancing intestinal phosphate absorption and reducing total phosphate requirements
3839245	1985	Clinical Study	Journal of Clinical Investigation	High-dose calcitriol heals osteomalacia in XLH patients unresponsive to conventional vitamin D; demonstrates that the active metabolite — not precursor forms — is required to correct the mineralisation defect in XLH
35226335	2022	Longitudinal Cohort	J Endocrinological Investigation	Growth trajectory from birth to adulthood in hereditary hypophosphatemic rickets; contextualises long-term treatment goals for calcitriol therapy, including disproportion in limb growth
29292875	2017	Multicenter Cohort	Pediatric Endocrinology Reviews	Height data from 127 XLH patients across 49 centres before and after initiation of calcitriol + phosphate therapy; supports early treatment initiation to optimise adult height outcomes
2492895	1989	Longitudinal Cohort	Calcified Tissue International	Bone mineral density measured at baseline and every 6 months in 17 children with familial hypophosphatemia on calcitriol + phosphate therapy; quantifies the skeletal mineralisation response to treatment

Netherlands Market Information

Calcitriol is not currently registered with the CBG-MEB (College ter Beoordeling van Geneesmiddelen) in the Netherlands. There are no active RVG authorisations on record. Prescribers wishing to use calcitriol for Dutch patients should consider the following regulatory pathways:

EU cross-border supply: Calcitriol products (e.g., Rocaltrol®) hold national authorisations in other EU member states including Germany and France; supply under Article 3.17 of the Dutch Medicines Act (Geneesmiddelenwet) may be applicable
Compounding (magistrale bereiding): Available through licensed Dutch compounding pharmacies under CBG-MEB oversight; suitable for individualised dosing in paediatric patients
EMA centralised pathway: No centrally authorised calcitriol product currently exists via EMA

The SmPC (Samenvatting van de Productkenmerken) from a relevant EU reference country should be consulted for authorised prescribing information until a Dutch authorisation is in place.

Safety Considerations

Formal pharmacovigilance data (regulatory warnings, contraindications, and drug-drug interactions) were not available in this evidence pack. Please refer to the SmPC for complete safety information.

Based on established pharmacology, the following considerations are particularly relevant when using calcitriol for hereditary hypophosphatemic rickets:

Hypercalcaemia and hypercalciuria: The most clinically significant adverse effects; calcitriol has a narrow therapeutic window. Regular monitoring of serum calcium and 24-hour urinary calcium is required, especially during dose titration and in growing children.
Nephrocalcinosis: A well-documented long-term complication of calcitriol + phosphate therapy in XLH. Renal ultrasound surveillance at regular intervals is recommended throughout treatment.
Secondary and tertiary hyperparathyroidism: Overtreatment or prolonged therapy can paradoxically drive PTH dysregulation. Serial PTH monitoring is essential.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Calcitriol’s role in hereditary hypophosphatemic rickets is mechanistically well-established and supported by decades of clinical data, including a landmark NEJM trial, multiple cohort studies, and an ongoing Phase 4 dose-comparison trial. The TxGNN prediction is consistent with established clinical practice, and the evidence level of L2 justifies moving forward. However, calcitriol is not registered in the Netherlands, and the newer targeted therapy burosumab (anti-FGF23) is now EMA-approved for XLH — requiring careful clinical and health-economic positioning before deployment in the Dutch healthcare context.

To proceed, the following is needed:

Obtain the SmPC from an EU reference country (Germany or France recommended) to confirm approved dosing, safety monitoring requirements, and contraindications
Clarify the regulatory pathway with CBG-MEB: Article 3.17 import, compounding, or initiating a formal NL/EU registration procedure
Review final results of NCT03820518 (Phase 4 high vs. low dose) when published to inform weight-based dosing decisions for paediatric patients
Conduct a comparative health technology assessment (calcitriol + phosphate vs. burosumab) for the Dutch patient population with hereditary hypophosphatemic rickets, including cost-effectiveness and access equity considerations
Establish a prospective safety monitoring protocol covering serum calcium, urinary calcium, PTH, renal function, and renal ultrasound prior to clinical deployment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.